Lead Product(s): Vafidemstat
Therapeutic Area: Neurology
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020
REIMAGINE-AD is a Phase IIa study to assess the effect of vafidemstat in agitation-aggression in moderate and severe AD patients.